TransMedics Group Inc

TMDX

Equity

ISIN US89377M1099 / Valor 47361695

NASDAQ (2025-04-04)

USD 67.67-4.64%

TransMedics Group Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

TransMedics Group Inc is a company that offers technology and clinical services aimed at improving heart and lung transplant procedures. Their flagship product, the TransMedics Organ Care System (OCS™), is the only FDA-approved technology for lung, heart, and liver transplantation in the U.S. The company's solutions are designed to maximize transplant volume, improve clinical outcomes, and reduce learning curves for medical professionals.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

TransMedics Group Inc. reported a significant increase in total revenue for the third quarter of 2024, reaching $108.8 million. This marks a 64% growth compared to the $66.4 million recorded in the third quarter of 2023. The revenue boost was primarily driven by the increased utilization of the Organ Care System (OCS) across all three organs through the National OCS Program (NOP) and additional revenue from TransMedics logistics services.

Net Income

For the third quarter of 2024, TransMedics Group Inc. achieved a net income of $4.2 million, translating to $0.12 per diluted share. This is a notable improvement from the net loss of $25.4 million reported in the same quarter of the previous year. The positive net income reflects the company's successful growth strategies and operational efficiencies.

Gross Margin

TransMedics Group Inc. reported a gross margin of 56% for the third quarter of 2024, a decrease from the 61% gross margin in the third quarter of 2023. The decline in gross margin is attributed to a higher proportion of service revenue, which typically carries a lower margin compared to product revenue, and investments made in the NOP network to support future growth.

Operating Expenses

Operating expenses for TransMedics Group Inc. in the third quarter of 2024 were $56.9 million, compared to $69.0 million in the third quarter of 2023. The previous year's expenses included $27.2 million of non-recurring in-process research and development. The increase in operating expenses was mainly due to higher research and development investments and organizational growth initiatives.

Financial Outlook

TransMedics Group Inc. maintains its financial outlook for the full year 2024, expecting revenue to be in the range of $425 million to $445 million. This projection represents a growth of 76% to 84% compared to the company's revenue in the prior year. The company remains confident in its growth trajectory and strategic initiatives for the upcoming years.

Summarized from source with an LLMView Source

Key figures

-12.3%1Y

145%3Y

470%5Y

Performance

73.2%1Y

74.3%3Y

74.6%5Y

Volatility